Berenberg Updates Price Target, Estimates for UCB on Recent Pipeline Deals
() -- Berenberg revised its price target and earnings forecasts for UCB (UCB.BR) to account for the biopharmaceutical company's recent acquisitions. "UCB recently closed three pipeline transactions: Candid Therapeutics, Neurona Therapeutics and Antengene. These deals bolster the immunology and neuroscience pipeline, ad